NCT06305715 Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

Trial Parameters

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This prospective, two-part, single-arm, phase II trial is designed to evaluate whether the use of definitive radiation to the primary lung lesion prolongs progression-free survival (PFS) in treatment-naïve, metastatic, driver-mutated non-small cell lung cancers (NSCLC) patients who are subsequently placed on a tyrosine kinase inhibitor (TKI).

Eligibility Criteria

Inclusion Criteria Part 1 1. Age ≥18 years. 2. Patient must have a pathologically-confirmed diagnosis of non-small cell lung cancer (NSCLC). 3. An identifiable primary lung lesion must be present based on the consensus opinion of the medical oncology and radiation oncology investigators. 4. Patient did not previously receive radiation therapy to the primary lung lesion. Previous or concurrent palliative radiation to symptomatic metastatic lesions and definitive radiation to central nervous system metastases are allowable. 5. Patient must have advanced disease, either stage IV or stage IIIB/C that is not amenable to definitive multi-modality therapy. 6. Patient must not have received prior targeted therapy for NSCLC. A subject may receive up to 2 cycles of standard cytotoxic chemotherapy for NSCLC prior to trial enrollment. For example, a cycle of carboplatin and pemetrexed is given once every 3 weeks. 7. Patient must have measurable disease as defined by RECIST v1.1. 8. Patient must ha

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.